Literature DB >> 11116046

Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.

L Bajzar1.   

Abstract

Coagulation and fibrinolysis are processes that form and dissolve fibrin, respectively. These processes are exquisitely regulated and protect the organism from excessive blood loss or excessive fibrin deposition. Regulation of these cascades is accomplished by a variety of mechanisms involving cellular responses, flow, and protein-protein interactions. With respect to regulation mediated by protein-protein interaction, the coagulation cascade appears to be more complex than the fibrinolytic cascade because it has more components. Yet each cascade is regulated by initiators, cofactors, feedback reactions, and inhibitors. Coagulation is also controlled by an anticoagulant pathway composed of (minimally) thrombin, thrombomodulin, and protein C.(1) Protein C is converted by the thrombin/thrombomodulin complex to activated protein C (APC), which catalyzes the proteolytic inactivation of the essential cofactors required for thrombin formation, factors Va and VIIIa. An analogous antifibrinolytic pathway has been identified recently. This pathway provides an apparent symmetry between coagulation and fibrinolysis and is also composed of thrombin, thrombomodulin, and a zymogen that is activated to an enzyme. The enzyme proteolytically inactivates a cofactor to attenuate fibrinolysis. However, unlike APC, which is a serine protease, the antifibrinolytic enzyme is a metalloprotease that exhibits carboxypeptidase B-like activity. Within a few years of each other, 5 groups independently described a molecule that accounts for this antifibrinolytic activity. We refer to this molecule as thrombin activatable fibrinolysis inhibitor (TAFI), a name that is based on functional properties by which it was identified, assayed, and purified. (Because of the preferences of some journals "activatable" is occasionally referred to as "activable.") This review will encompass a historical account of efforts to isolate TAFI and characterize it with respect to its activation, activity, regulation, and potential function in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11116046     DOI: 10.1161/01.atv.20.12.2511

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.

Authors:  Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD).

Authors:  N Assy; S Schlesinger; O Hussein
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Molecular intercommunication between the complement and coagulation systems.

Authors:  Umme Amara; Michael A Flierl; Daniel Rittirsch; Andreas Klos; Hui Chen; Barbara Acker; Uwe B Brückner; Bo Nilsson; Florian Gebhard; John D Lambris; Markus Huber-Lang
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

4.  Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.

Authors:  Evren Fidan; Halil Kavgaci; Asim Orem; Mustafa Yilmaz; Bulent Yildiz; Sami Fidan; Buket Akcan; Feyyaz Ozdemir; Fazil Aydin
Journal:  Tumour Biol       Date:  2012-04-27

5.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

6.  The influence of level of spinal cord injury on adipose tissue and its relationship to inflammatory adipokines and cardiometabolic profiles.

Authors:  Gary J Farkas; Ashraf S Gorgey; David R Dolbow; Arthur S Berg; David R Gater
Journal:  J Spinal Cord Med       Date:  2017-07-30       Impact factor: 1.985

7.  In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis.

Authors:  I K Mullarky; F M Szaba; C G Winchel; M A Parent; L W Kummer; N Mackman; L L Johnson; S T Smiley
Journal:  J Thromb Haemost       Date:  2006-07       Impact factor: 5.824

8.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

Review 9.  Pharmacologic reperfusion therapy for acute myocardial infarction.

Authors:  Harry C Lowe; Briain D Mac Neill; Frans Van de Werf; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

10.  A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.

Authors:  Nobuaki Okumura; Tomohiko Koh; Yuichi Hasebe; Taiichiro Seki; Toyohiko Ariga
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.